NASDAQ:QTRX - Quanterix Stock Price, News, Headlines & Rumors

Sign in or create an account to add this stock to your watchlist.
$14.65 +0.29 (+2.02 %)
(As of 08/17/2018 04:00 PM ET)
Previous Close$14.36
Today's Range$14.02 - $14.85
52-Week Range$13.00 - $24.81
Volume19,600 shs
Average Volume102,165 shs
Market Capitalization$323.03 million
P/E Ratio-1.73
Dividend YieldN/A
BetaN/A
Quanterix logoQuanterix Corporation, a life sciences company, develops and markets ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific. It develops Simoa HD-1 Analyzer, a sensitive protein detection platform, which analyzes approximately six biomarkers per test; and Quanterix SR-X, which utilizes the same technology and assay kit as the Simoa HD-1 Analyzer. The company's products include kits, such as beads, capture and detector reagents, enzyme reagents, and enzyme substrates to run tests; and consumables, such as proprietary Simoa disks, cuvettes, and disposable tips. In addition, it offers contract research services, including sample testing, homebrew assay development, and custom development services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sell its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct sales force, support organizations, and distributors or sales agents. Quanterix Corporation has a collaboration agreement with DestiNA Genomics to focus on the development of a nucleic acid assay for direct detection and quantification of the liver toxicity biomarker microRNA-122. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Lexington, Massachusetts.

Receive QTRX News and Ratings via Email

Sign-up to receive the latest news and ratings for QTRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Analytical instruments
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:QTRX
CUSIPN/A
Phone617-301-9400

Debt

Debt-to-Equity RatioN/A
Current Ratio3.36
Quick Ratio3.13

Price-To-Earnings

Trailing P/E Ratio-1.73
Forward P/E Ratio-12.21
P/E GrowthN/A

Sales & Book Value

Annual Sales$22.87 million
Price / Sales14.16
Cash FlowN/A
Price / CashN/A
Book Value$3.02 per share
Price / Book4.85

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees126
Outstanding Shares22,100,000
Market Cap$323.03 million

Quanterix (NASDAQ:QTRX) Frequently Asked Questions

What is Quanterix's stock symbol?

Quanterix trades on the NASDAQ under the ticker symbol "QTRX."

How were Quanterix's earnings last quarter?

Quanterix Corp (NASDAQ:QTRX) posted its quarterly earnings data on Wednesday, May, 9th. The company reported ($0.33) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.25) by $0.08. The company earned $7.52 million during the quarter, compared to the consensus estimate of $7.25 million. View Quanterix's Earnings History.

When is Quanterix's next earnings date?

Quanterix is scheduled to release their next quarterly earnings announcement on Friday, November, 9th 2018. View Earnings Estimates for Quanterix.

What price target have analysts set for QTRX?

4 brokerages have issued 1-year price objectives for Quanterix's shares. Their forecasts range from $26.00 to $27.00. On average, they anticipate Quanterix's share price to reach $26.50 in the next year. This suggests a possible upside of 80.9% from the stock's current price. View Analyst Price Targets for Quanterix.

What is the consensus analysts' recommendation for Quanterix?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Quanterix in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Quanterix.

What are Wall Street analysts saying about Quanterix stock?

Here are some recent quotes from research analysts about Quanterix stock:
  • 1. According to Zacks Investment Research, "Quanterix Corporation is a developer of tools in high definition diagnostics. The Company focuses on research and diagnostics for brain injuries, heart disease, cancer and other diseases with its technology. It offers Simoa consumables, which include Simoa Discs, Simoa Cuvettes, Simoa Sealing Oil, Simoa Buffers and Disposable Tips. The company services include Simoa Accelerator Lab and custom assay development services. Quanterix Corporation is based in LEXINGTON, United States. " (8/14/2018)
  • 2. BTIG Research analysts commented, "Acceleration, and Expanding NT PT:1Q18 revenue growth of +41% exceeded consensus of +33% driven by strength in higher margin consumable and service revenue growth. Pharma/Biotech/CRO segment (46% of revenue) grew +48%, and Academic (46% of revenue) grew +33%. Academic should continue to strengthen with the recent launch of SR-X (1Q represented first full quarter of commercial sales; Asia launch on target for 2Q). While formal guidance for the full year remains unavailable, management is committed to delivering consensus expectations (~50% revenue growth). Looking ahead, QTRX expects to increase its sales force emphasis on the Accelerator business NT leveraging its recently acquired CLIA lab facilities (Aushon tuck-in), and in order to capitalize on the recent regulatory developments increasingly focusing on biomarker incorporation throughout biopharma preclinical/clinical trials." (5/13/2018)

Who are some of Quanterix's key competitors?

Who are Quanterix's key executives?

Quanterix's management team includes the folowing people:
  • Mr. E. Kevin Hrusovsky, Chairman, Pres & CEO (Age 57)
  • Dr. David R. Walt, Co-Founder, Chairman of Scientific Advisory Board & Director (Age 65)
  • Mr. Bruce J. Bal, VP of Operations, Service & Quality (Age 59)
  • Dr. Mark T. Roskey, Sr. VP and GM of Applications & Reagents (Age 58)
  • Mr. Joseph S. Driscoll, Chief Financial Officer (Age 53)

When did Quanterix IPO?

(QTRX) raised $50 million in an initial public offering (IPO) on Thursday, December 7th 2017. The company issued 3,300,000 shares at $14.00-$16.00 per share. J.P. Morga and Leerink Partners acted as the underwriters for the IPO and BTIG and Evercore ISI were co-managers.

Has Quanterix been receiving favorable news coverage?

News stories about QTRX stock have trended somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies positive and negative news coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Quanterix earned a news impact score of 0.09 on Accern's scale. They also gave news headlines about the company an impact score of 46.37 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near term. View Recent Headlines for Quanterix.

Who are Quanterix's major shareholders?

Quanterix's stock is owned by many different of retail and institutional investors. Top institutional investors include Gilder Gagnon Howe & Co. LLC (4.97%), Royce & Associates LP (2.18%), Jennison Associates LLC (1.60%), BlackRock Inc. (1.12%), Bellevue Group AG (0.75%) and Millennium Management LLC (0.68%). Company insiders that own Quanterix stock include David R Walt, E Kevin Hrusovsky, Ernest Orticerio and Venture Fund Viii Overage Arch. View Institutional Ownership Trends for Quanterix.

Which institutional investors are selling Quanterix stock?

QTRX stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC. View Insider Buying and Selling for Quanterix.

Which institutional investors are buying Quanterix stock?

QTRX stock was acquired by a variety of institutional investors in the last quarter, including Gilder Gagnon Howe & Co. LLC, Royce & Associates LP, Bellevue Group AG, BlackRock Inc., TD Asset Management Inc., Pendal Group Ltd, Bank of New York Mellon Corp and First Republic Investment Management Inc.. Company insiders that have bought Quanterix stock in the last two years include David R Walt, E Kevin Hrusovsky and Venture Fund Viii Overage Arch. View Insider Buying and Selling for Quanterix.

How do I buy shares of Quanterix?

Shares of QTRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Quanterix's stock price today?

One share of QTRX stock can currently be purchased for approximately $14.65.

How big of a company is Quanterix?

Quanterix has a market capitalization of $323.03 million and generates $22.87 million in revenue each year. The company earns $-27,010,000.00 in net income (profit) each year or ($8.30) on an earnings per share basis. Quanterix employs 126 workers across the globe.

How can I contact Quanterix?

Quanterix's mailing address is 113 HARTWELL AVENUE, LEXINGTON MA, 02421. The company can be reached via phone at 617-301-9400.


MarketBeat Community Rating for Quanterix (NASDAQ QTRX)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  103 (Vote Outperform)
Underperform Votes:  109 (Vote Underperform)
Total Votes:  212
MarketBeat's community ratings are surveys of what our community members think about Quanterix and other stocks. Vote "Outperform" if you believe QTRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe QTRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/17/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.